The changes of interleukin-18 and interleukin-33 expression level in chronic urticaria patients before and after being treated with desloratadine citrate disodium
Abstract：ObjectiveTo investigate the possible role and clinical signiifcance of interleukin (IL)-18 and IL-33 in the pathogenesis of chronic urticaria (CU).MethodsDouble-antibody sandwich immunosorbent assay (ABC-ELISA) was performed to detect the differential expression of IL-18 and IL-33 in peripheral blood in 60 CU patients and 50 normal controls, as well as the differential expression of IL-18 and IL-33 in CU patients before and after being treated with desloratadine citrate disodium, ifnally the correlation between the expression of IL-18, IL-33 and clinical efifcacy of desloratadine citrate disodium was investigated.ResultsThe level of IL-18 in serum of CU patients before treatment was signiifcantly higher than that of the healthy control group (P<0.05). At the end of 4 weeks of treatment, the level of IL-18 in serum was signiifcantly lower than that of before treatment (P<0.05), whereas compared with the control group, there was no signiifcant difference (P>0.05). No signiifcant difference was observed in the level of IL-33 between the healthy control group and CU group before and after the treatment (P>0.05). The changes in the concentration of IL-18 before and after treatment in CU patients and its clinical therapeutic effect were positively correlated.ConclusionIL-18 may be involved in pathological processes in the pathogenesis of CU, but the role of IL-33 needs further study. Desloratadine citrate disodium is an ideal antihistamine to treat CU which could regulate the expression of cytokines involved in the pathogenesis of CU.
Keywords：UrticariachronicInterleukin-18Interleukin-33Desloratadine citrate disodium
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 22-24 )